AustralianSuper Pty Ltd Purchases 95,052 Shares of Cigna Group $CI

AustralianSuper Pty Ltd increased its position in shares of Cigna Group (NYSE:CI) by 816.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 106,699 shares of the health services provider’s stock after buying an additional 95,052 shares during the period. AustralianSuper Pty Ltd’s holdings in Cigna Group were worth $30,756,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in CI. Pathway Financial Advisers LLC lifted its position in shares of Cigna Group by 2.3% in the 2nd quarter. Pathway Financial Advisers LLC now owns 1,501 shares of the health services provider’s stock worth $496,000 after purchasing an additional 34 shares during the period. Armstrong Advisory Group Inc. raised its stake in Cigna Group by 17.7% in the third quarter. Armstrong Advisory Group Inc. now owns 226 shares of the health services provider’s stock worth $65,000 after buying an additional 34 shares in the last quarter. HM Payson & Co. raised its stake in Cigna Group by 0.9% in the third quarter. HM Payson & Co. now owns 3,785 shares of the health services provider’s stock worth $1,091,000 after buying an additional 35 shares in the last quarter. Carr Financial Group Corp lifted its holdings in Cigna Group by 5.3% during the third quarter. Carr Financial Group Corp now owns 709 shares of the health services provider’s stock worth $204,000 after buying an additional 36 shares during the period. Finally, Natural Investments LLC boosted its position in Cigna Group by 2.0% during the 3rd quarter. Natural Investments LLC now owns 1,843 shares of the health services provider’s stock valued at $531,000 after acquiring an additional 36 shares in the last quarter. 86.99% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on CI shares. The Goldman Sachs Group reduced their price target on Cigna Group from $370.00 to $330.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Cigna Group from $301.00 to $304.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Zacks Research upgraded shares of Cigna Group from a “strong sell” rating to a “hold” rating in a report on Monday, January 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Cigna Group in a research note on Monday, December 29th. Finally, Robert W. Baird decreased their target price on shares of Cigna Group from $372.00 to $315.00 and set an “outperform” rating for the company in a research report on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, Cigna Group has a consensus rating of “Moderate Buy” and an average price target of $330.42.

Insider Activity

In other news, insider Everett Neville sold 1,719 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $288.91, for a total value of $496,636.29. Following the transaction, the insider directly owned 5,670 shares of the company’s stock, valued at approximately $1,638,119.70. This represents a 23.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Nicole S. Jones sold 2,307 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $288.91, for a total value of $666,515.37. Following the completion of the transaction, the insider owned 32,647 shares of the company’s stock, valued at approximately $9,432,044.77. The trade was a 6.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.70% of the stock is currently owned by insiders.

Trending Headlines about Cigna Group

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Piper Sandler kept an Overweight rating on CI and cut its price target slightly to $370 (from $374), implying roughly 30% upside from current levels — a vote of confidence from an institutional analyst. Piper Sandler price target story
• Positive Sentiment: Cigna reaffirmed its 2026 financial outlook while announcing the succession plan and said Brian Evanko was elected to the board — the reaffirmation reduces immediate earnings guidance risk. PR Newswire release
• Positive Sentiment: Analyst/strategy pieces (e.g., Zacks) continue to highlight Cigna’s growth characteristics and strong fundamentals after recent results, supporting a longer-term constructive view. Zacks analysis
• Neutral Sentiment: Cigna executives (CFO Ann Dennison and Evernorth president Adam Kautzner) presented at the TD Cowen healthcare conference this week — useful for investor Q&A but not a major catalyst. TD Cowen presentation notice
• Neutral Sentiment: Corporate/regional PR (e.g., broker awards in Dubai) highlights distribution/partner relationships but is unlikely to move the stock materially. BusinessWire awards story
• Negative Sentiment: The market reacted negatively to the announced CEO succession: long-time CEO David Cordani will retire July 1, 2026 and become executive chair while President/COO Brian Evanko becomes CEO. Coverage flagged investor concern about leadership change despite Evanko being an internal choice; that concern appears to be the primary near-term reason for the stock decline. Seeking Alpha on leadership transition

Cigna Group Stock Performance

Shares of Cigna Group stock opened at $283.58 on Wednesday. The company has a 50 day moving average price of $280.48 and a 200 day moving average price of $284.45. The firm has a market capitalization of $74.73 billion, a P/E ratio of 12.79, a PEG ratio of 1.01 and a beta of 0.27. The company has a quick ratio of 0.74, a current ratio of 0.74 and a debt-to-equity ratio of 0.74. Cigna Group has a 52 week low of $239.51 and a 52 week high of $350.00.

Cigna Group (NYSE:CI) last issued its quarterly earnings results on Thursday, February 5th. The health services provider reported $8.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.88 by $0.20. The business had revenue of $72.50 billion for the quarter, compared to analyst estimates of $69.53 billion. Cigna Group had a net margin of 2.17% and a return on equity of 19.46%. Cigna Group’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.64 EPS. Cigna Group has set its FY 2026 guidance at 30.250- EPS. Sell-side analysts expect that Cigna Group will post 29.77 EPS for the current year.

Cigna Group Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Thursday, March 5th will be given a dividend of $1.56 per share. The ex-dividend date of this dividend is Thursday, March 5th. This represents a $6.24 dividend on an annualized basis and a yield of 2.2%. This is an increase from Cigna Group’s previous quarterly dividend of $1.51. Cigna Group’s payout ratio is presently 27.23%.

Cigna Group Company Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.